For instance, the tyrosine kinase inhibitor Imatinib was developed to target the fusion gene BCR-ABL, which is constitutively activated in chronic myeloid leukemia (CML). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.